Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABEO NASDAQ:ALKS NASDAQ:MEDP NASDAQ:OMCL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.27-2.6%$6.22$3.93▼$7.54$270.25M1.42999,611 shs25,693 shsALKSAlkermes$32.05-0.4%$28.76$25.17▼$36.45$5.29B0.541.79 million shs81,420 shsMEDPMedpace$523.25-0.8%$485.22$250.05▼$547.15$14.70B1.4426,522 shs8,170 shsOMCLOmnicell$29.28-0.6%$31.57$22.66▼$55.74$1.34B0.88546,515 shs6,070 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+0.93%+1.31%-15.86%-9.08%-15.60%ALKSAlkermes+3.08%+3.81%+19.28%+11.51%+11.28%MEDPMedpace+5.22%-0.55%+7.49%+68.65%+51.59%OMCLOmnicell-0.87%-3.47%-7.45%+8.15%-30.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$5.27-2.6%$6.22$3.93▼$7.54$270.25M1.42999,611 shs25,693 shsALKSAlkermes$32.05-0.4%$28.76$25.17▼$36.45$5.29B0.541.79 million shs81,420 shsMEDPMedpace$523.25-0.8%$485.22$250.05▼$547.15$14.70B1.4426,522 shs8,170 shsOMCLOmnicell$29.28-0.6%$31.57$22.66▼$55.74$1.34B0.88546,515 shs6,070 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics+0.93%+1.31%-15.86%-9.08%-15.60%ALKSAlkermes+3.08%+3.81%+19.28%+11.51%+11.28%MEDPMedpace+5.22%-0.55%+7.49%+68.65%+51.59%OMCLOmnicell-0.87%-3.47%-7.45%+8.15%-30.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics 2.83Moderate Buy$19.50270.02% UpsideALKSAlkermes 2.93Moderate Buy$42.0031.05% UpsideMEDPMedpace 1.94Reduce$424.10-18.95% DownsideOMCLOmnicell 2.38Hold$46.7159.54% UpsideCurrent Analyst Ratings BreakdownLatest ALKS, ABEO, MEDP, and OMCL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/13/2025ABEOAbeona TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.0010/8/2025ABEOAbeona TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)10/8/2025MEDPMedpaceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)10/8/2025OMCLOmnicellWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025ABEOAbeona TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025ALKSAlkermesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025MEDPMedpaceWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)9/27/2025OMCLOmnicellWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/26/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSector Perform ➝ Outperform$42.00 ➝ $44.009/22/2025MEDPMedpaceZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/9/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$43.00(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M77.21N/AN/A$1.01 per share5.22ALKSAlkermes$1.56B3.40$2.72 per share11.77$9.05 per share3.54MEDPMedpace$2.11B6.97$14.56 per share35.93$26.56 per share19.70OMCLOmnicell$1.11B1.21$3.02 per share9.71$26.84 per share1.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$63.73M$0.707.53N/AN/AN/A89.05%45.64%11/13/2025 (Estimated)ALKSAlkermes$367.07M$2.0815.4123.391.6923.15%24.86%17.14%10/23/2025 (Estimated)MEDPMedpace$404.39M$13.4538.9038.303.1418.74%67.66%21.86%10/22/2025 (Estimated)OMCLOmnicell$12.53M$0.5058.5623.616.492.01%4.27%2.44%10/30/2025 (Estimated)Latest ALKS, ABEO, MEDP, and OMCL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/30/2025Q3 2025OMCLOmnicell$0.36N/AN/AN/A$295.59 millionN/A10/23/2025Q3 2025ALKSAlkermes$0.41N/AN/AN/A$355.23 millionN/A10/22/2025Q3 2025MEDPMedpace$3.49N/AN/AN/A$640.49 millionN/A8/14/2025Q2 2025ABEOAbeona Therapeutics-$0.39$1.71+$2.10$1.71$21.71 million$0.40 million7/31/2025Q2 2025OMCLOmnicell$0.30$0.45+$0.15$0.12$275.57 million$290.56 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 million7/21/2025Q2 2025MEDPMedpace$3.00$3.10+$0.10$3.10$537.70 million$603.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AALKSAlkermesN/AN/AN/AN/AN/AMEDPMedpaceN/AN/AN/AN/AN/AOMCLOmnicellN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona Therapeutics0.096.736.65ALKSAlkermesN/A3.232.85MEDPMedpaceN/A0.430.43OMCLOmnicell0.131.421.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%ALKSAlkermes95.21%MEDPMedpace77.98%OMCLOmnicell97.70%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.40%ALKSAlkermes4.40%MEDPMedpace20.30%OMCLOmnicell2.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona Therapeutics9051.28 million48.51 millionOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableMEDPMedpace5,90028.09 million22.39 millionOptionableOMCLOmnicell3,67045.93 million44.78 millionOptionableALKS, ABEO, MEDP, and OMCL HeadlinesRecent News About These CompaniesOmnicell (NASDAQ:OMCL) Given Sell (D+) Rating at Weiss RatingsOctober 10, 2025 | marketbeat.comShareholders in Omnicell (NASDAQ:OMCL) are in the red if they invested five years agoOctober 8, 2025 | finance.yahoo.comIs Omnicell (OMCL) Stock Undervalued Right Now?October 7, 2025 | zacks.comReasons to Add Omnicell Stock to Your Portfolio Right NowOctober 7, 2025 | zacks.comContrasting Alternate Health (OTCMKTS:AHGIF) and Omnicell (NASDAQ:OMCL)October 7, 2025 | americanbankingnews.comOmnicell Updates Bylaws for Enhanced GovernanceOctober 6, 2025 | tipranks.comOmnicell to Release Third Quarter 2025 Financial Results on October 30, 2025October 6, 2025 | businesswire.comHunter Perkins Capital Management LLC Buys Shares of 9,370 Omnicell, Inc. $OMCLOctober 6, 2025 | marketbeat.comAnalysts Set Omnicell, Inc. (NASDAQ:OMCL) PT at $46.71October 3, 2025 | americanbankingnews.com1 Stock Under $50 with Promising Prospects and 2 Facing ChallengesOctober 2, 2025 | msn.comOMCL or HIMS: Which Is the Better Value Stock Right Now?October 1, 2025 | zacks.comOmnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 30, 2025 | marketbeat.comAssenagon Asset Management S.A. Trims Stock Position in Omnicell, Inc. $OMCLSeptember 29, 2025 | marketbeat.comCraig-Hallum Reaffirms Their Buy Rating on Omnicell (OMCL)September 25, 2025 | theglobeandmail.comDiversified Trust Co Cuts Stock Position in Omnicell, Inc. $OMCLSeptember 25, 2025 | marketbeat.comAccurate Wealth Management LLC Has $1.37 Million Stock Position in Omnicell, Inc. $OMCLSeptember 24, 2025 | marketbeat.comOmnicell (NASDAQ:OMCL) Share Price Passes Above 200-Day Moving Average - What's Next?September 24, 2025 | marketbeat.comIs Omnicell (OMCL) a Great Value Stock Right Now?September 18, 2025 | zacks.comInsider Selling: Omnicell (NASDAQ:OMCL) EVP Sells 3,880 Shares of StockSeptember 17, 2025 | marketbeat.comOmnicell (NASDAQ:OMCL) EVP Sells $129,010.00 in StockSeptember 17, 2025 | insidertrades.comStrs Ohio Takes $5.64 Million Position in Omnicell, Inc. $OMCLSeptember 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Why the Precious Metal Nobody Talks About Could Be Your Best BetBy Jordan Chussler | October 4, 2025ALKS, ABEO, MEDP, and OMCL Company DescriptionsAbeona Therapeutics NASDAQ:ABEO$5.27 -0.14 (-2.59%) As of 09:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Alkermes NASDAQ:ALKS$32.05 -0.12 (-0.37%) As of 09:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Medpace NASDAQ:MEDP$523.24 -4.16 (-0.79%) As of 09:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.Omnicell NASDAQ:OMCL$29.28 -0.18 (-0.61%) As of 09:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
